Dynavax Technologies Co. (NASDAQ:DVAX) Short Interest Update

Dynavax Technologies Co. (NASDAQ:DVAXGet Free Report) was the recipient of a large growth in short interest during the month of May. As of May 15th, there was short interest totalling 22,700,000 shares, a growth of 15.7% from the April 30th total of 19,620,000 shares. Based on an average daily trading volume, of 2,070,000 shares, the short-interest ratio is presently 11.0 days.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $29.00 price target on shares of Dynavax Technologies in a research note on Thursday, May 9th. StockNews.com cut Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, May 28th. Finally, William Blair restated an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 23rd. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Dynavax Technologies presently has a consensus rating of “Moderate Buy” and an average target price of $25.33.

View Our Latest Stock Analysis on DVAX

Hedge Funds Weigh In On Dynavax Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in DVAX. DekaBank Deutsche Girozentrale acquired a new stake in shares of Dynavax Technologies in the 3rd quarter valued at about $33,000. Advisor Resource Council bought a new position in shares of Dynavax Technologies during the 4th quarter worth approximately $144,000. Rathbones Group PLC purchased a new position in Dynavax Technologies in the third quarter worth $158,000. China Universal Asset Management Co. Ltd. purchased a new position in Dynavax Technologies in the fourth quarter worth $209,000. Finally, Duality Advisers LP bought a new position in Dynavax Technologies in the 1st quarter valued at $227,000. 96.96% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies Price Performance

Shares of DVAX traded up $0.17 during mid-day trading on Friday, reaching $11.99. The company had a trading volume of 2,934,354 shares, compared to its average volume of 2,187,169. The company has a market capitalization of $1.57 billion, a price-to-earnings ratio of 199.83 and a beta of 1.30. The company has a debt-to-equity ratio of 0.36, a quick ratio of 14.10 and a current ratio of 15.20. The company’s 50 day simple moving average is $11.69 and its 200 day simple moving average is $12.73. Dynavax Technologies has a 1-year low of $10.48 and a 1-year high of $15.15.

Dynavax Technologies (NASDAQ:DVAXGet Free Report) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The firm had revenue of $50.79 million for the quarter, compared to the consensus estimate of $51.98 million. Dynavax Technologies had a return on equity of 1.52% and a net margin of 3.91%. Analysts expect that Dynavax Technologies will post 0.12 EPS for the current year.

About Dynavax Technologies

(Get Free Report)

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Featured Stories

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.